Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2009 Nov 1.

Published in final edited form as: Cancer Invest. 2008 Nov;26(9):956–963. doi: 10.1080/07357900802132550

Figure 2a and Figure 2b — Figure 2a. Kaplan-Meier estimate of disease-free survival in the MOSAIC trial.

Reproduced with permission from: André, Boni, Mounedji-Boudiaf, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350:2343–51. Copyright© 2004 Massachusetts Medical Society. All rights reserved.

Figure 2b: Kaplan-Meier estimate of disease-free survival in the NSABP C-07 trial.

Adapted from Figure 2, Kuebler JP et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 25 (16), 2007: 2198–2204. Reprinted with permission.

Figure 2a and Figure 2b — Figure 2a. Kaplan-Meier estimate of disease-free survival in the MOSAIC trial.

Reproduced with permission from: André, Boni, Mounedji-Boudiaf, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350:2343–51. Copyright© 2004 Massachusetts Medical Society. All rights reserved.

Figure 2b: Kaplan-Meier estimate of disease-free survival in the NSABP C-07 trial.

Adapted from Figure 2, Kuebler JP et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 25 (16), 2007: 2198–2204. Reprinted with permission.